Simethicone Solution — Competitive Intelligence Brief

Simethicone Solution (Simethicone Solution) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifoaming agent. Area: Gastroenterology.

marketed Antifoaming agent Gastroenterology Small molecule

Target snapshot

Simethicone Solution (Simethicone Solution) — University of Nevada, Reno. Simethicone reduces surface tension of gas bubbles in the gastrointestinal tract, allowing them to coalesce and be expelled more easily.

Comparator set (4 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Simethicone Solution TARGET	Simethicone Solution	University of Nevada, Reno	marketed	Antifoaming agent
High Volume Simethicone	High Volume Simethicone	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	marketed	Antifoaming agent
Standard Volume Simethicone	Standard Volume Simethicone	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	marketed	Antifoaming agent
Loperamide hydrochloride + simethicone chewable tablet	Loperamide hydrochloride + simethicone chewable tablet	Xian-Janssen Pharmaceutical Ltd.	phase 3	Antidiarrheal and antifoaming agent	μ-opioid receptors, gas bubbles
Mebeverine+Simethicone	Mebeverine+Simethicone	Abbott	phase 3	Antispasmodic + antifoaming agent combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifoaming agent class)

1. London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · 2 drugs in this class
2. University of Nevada, Reno · 1 drug in this class